NCT00003457View on ClinicalTrials.gov

Antineoplaston Therapy in Treating Patients With Brain Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 1996

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Refractory Brain Tumors
Interventions
DRUG

Antineoplaston therapy (Atengenal + Astugenal)

Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER